GFR Pharmaceuticals Inactive 10-Q2011 Q1 Quarterly report

Filed: 13 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absorption, accelerated, accurately, administering, advertisement, agricultural, appoint, approval, approved, assignment, Biosep, case, Certificate, chapter, check, Chuan, clinical, commencement, contract, Cooperation, cope, Dan, debt, detail, Director, disposition, Drug, effort, electronically, Employer, Engineering, ensure, event, expired, external, Fang, fifty, filer, flow, Food, Fu, goodwill, heart, hree, ID, indirect, Interactive, issuer, Jiao, judgment, Kang, laboratory, latent, leading, listed, margin, mark, Masep, mask, Nang, newly, opposed, option, par, past, patent, percent, Pertain, Ping, point, post, posted, power, preceding, precision, previously, project, qualitative, recognizable, reduce, relationship, reliability, renewed, restructuring, Road, Science, seq, seventy, SFDA, Shanxi, shell, Shenzhen, shorter, site, sixteen, sooner, spent, step, submit, submitted, successful, Tandgu, telephone, termination, Tong, toxic, toxicology, traditional, TRANSITION, treat, trial, troubled, twelve, unadjusted, unauthorized, undertook, Washington, Web, Xiang, Xin

Removed: absence, advance, affiliate, affiliated, allocate, Bai, Broadly, classification, classified, conform, consideration, deficit, developing, EITF, exit, experience, Fourth, framework, governing, hypothetical, identifiable, identified, July, Military, open, orderly, paid, participant, pay, policy, presentation, prior, raw, receive, recent, reclassified, requiring, sell, Shaanxi, slight, specifically, standard, uncollectible, unconsolidated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GFR Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

UNDER SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the quarterly report on Form 10-Q of GFR Pharmaceuticals, Inc. (the “Company”) for the quarter ended March 31, 2011 as filed with the Securities and Exchange Commission as of the date hereof (the "Report"), I, Zhao Yan Ding, the chief executive officer of us, hereby certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 13, 2011

	By:	/s/ Zhao Yan Ding
	Zhao Yan Ding, CEO